SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

14 Feb 2026 Evaluate
The Revenue for the quarter ended  December 2025 of Rs. 18451.80 millions grew by 10.98 % from Rs. 16626.80 millions.A slim rise of 13.41% was recorded in the Net profit for the quarter ended December 2025 to Rs. 3034.50  millions  From Rs. 2675.60 millions.Operating Profit saw a handsome growth to 4953.00 millions from 4285.00 millions in the quarter ended December 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 18451.80 16626.80 10.98 55224.00 50394.80 9.58 66779.20 61664.60 8.29
Other Income 178.20 174.10 2.35 647.60 498.00 30.04 712.90 1112.90 -35.94
PBIDT 4953.00 4285.00 15.59 14138.70 12162.40 16.25 15963.20 13226.70 20.69
Interest 95.10 101.70 -6.49 330.30 468.40 -29.48 630.40 1206.70 -47.76
PBDT 4857.90 4183.30 16.13 13808.40 11694.00 18.08 12517.40 10686.40 17.13
Depreciation 685.70 628.10 9.17 1985.60 1867.80 6.31 2519.70 2464.80 2.23
PBT 4172.20 3555.20 17.35 11822.80 9826.20 20.32 9997.70 8221.60 21.60
TAX 1137.70 879.60 29.34 3120.50 2668.10 16.96 3490.10 2917.50 19.63
Deferred Tax 29.40 -15.40 -290.91 40.40 18.10 123.20 81.10 37.40 116.84
PAT 3034.50 2675.60 13.41 8702.30 7158.10 21.57 6507.60 5304.10 22.69
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 26.84 25.77 4.16 25.60 24.13 6.08 23.90 21.45 11.45

Ipca Laboratories Share Price

1468.00 6.75 (0.46%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×